Objective: To assess the impact of a weight management program on metabolic health of second-generation antipsychotic (SGA)-treated patients.
S GAs are now the cornerstone of schizophrenia treatment, offering an increased spectrum of efficacy. 1, 2 However, use of SGAs has been associated with significant weight gain, 3 accompanied by a cluster of metabolic disturbances, [4] [5] [6] hence increasing the risk of cardiovascular diseases. 7, 8 Moreover, there is an increasing health concern regarding the enhanced prevalence of the metabolic syndrome among patients with schizophrenia 9,10 as well as concerns that SGAs may contribute to this problem. 11 It is evident that SGAs, combined with poor lifestyle habits generally observed in this population, 12 may enhance the cardiovascular risk.
There is currently considerable evidence that weight loss achieved through lifestyle interventions is generally associated with significant improvements in the cardiovascular risk profile. 13 Moreover, an increased energy expenditure associated with an exercise training program could improve insulin action and the metabolic risk profile in the absence of weight loss. 14 Further, it is well documented that a sedentary lifestyle contributes to dyslipidemia and to an altered metabolic risk profile that characterize overweight or obese people. 15 This intervention study was designed to assess the impact of a 12-week weight management program on metabolic risk factors among SGA-treated patients (intervention group), compared with reference SGA-treated patients (reference group).
Methods

Patients
The 6 patients participating in the intervention program (5 men and 1 woman) were all volunteers from an outpatient psychiatric clinic and the study protocol was performed in accordance with the Declaration of Helsinki. 16 They were all under SGA treatment (clozapine: n = 3, olanzapine: n = 1, clozapine + olanzapine: n = 1, risperidone + quetiapine: n = 1). The reference group was composed of 10 patients (8 men and 2 women) from an early intervention program for psychotic patients, by similar age, physical activity level, and duration of current SGA treatment (olanzapine: n = 5, quetiapine: n = 2, risperidone: n = 2, ziprasidone: n = 1). The Ethics Review Board of the Centre de Recherche Université Laval Robert-Giffard approved the study, and a signed informed consent form was obtained from all patients in the reference group. For patients in both groups, treatment with concomitant medication for depression, anxiety, and (or) mood disorders were not considered as exclusion criteria, whereas patients treated with drugs altering blood pressure, plasma lipids, insulin, glucose, and body weight were excluded. Patients also had to be aged between 18 and 65 years (outpatients) and had to be sedentary at baseline (practicing less than 30 minutes of continuous physical activity per week). Patients were diagnosed by their referring psychiatrist using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.
Intervention Program
The intervention program was based on 3 major components involved in lifestyle management of overweight and obese people: physical activity, nutritional counselling, and behavioural education. 17 For physical activity, patients were asked to exercise at least twice a week for a maximum of 12 weeks (24 sessions). Exercise parameters were not pre-established to stimulate and reward any type of participation. Compliance to the training program was calculated as the percentage of training sessions performed on the total prescription of exercise sessions.
For nutritional counselling, 6 interactive adapted nutritional group sessions were proposed. Topics were based on the composition of food and on daily nutritional recommended servings according to Canada's Food Guide. 18 Each group session ended with a little snack to initiate changes in eating habits. Finally, education was introduced in 3 health capsules given by a registered nurse aiming to increase awareness of the impact of being overweight on metabolic health.
Measurements
For patients of both groups, anthropometric measurements and a basic lipid profile were performed following standardized procedures before and after the 12-week period. 19 For patients of the intervention group, we performed an adapted Rockport Test 20 to evaluate their aerobic fitness. Patients were asked to walk 1.6 kilometres at an intensity near 70% of their maximal aerobic capacity. This intensity was determined for each patient by using the standard Karvonen formula. 21 The lapse of time in minutes to go through the distance was measured and taken as the Aerobic Fitness Index.
Statistical Analyses
Paired t tests were performed (SAS, version 8.0; SAS Institute, Cary, NC) to test the significance of changes in variables measured over the 12-week period in each group, and unpaired t tests were performed to test the differences in baseline characteristics between the 2 groups as well as the 12-week interaction. When female patients were removed from statistical analyses, results remained significant. Thus they were kept in the samples. The threshold for statistical significance was set at 0.05 (2-tailed). 
Results
As demonstrated in Table 1 , baseline data suggest that patients in both groups were, overall, overweight or obese 22 and also characterized by the hypertriglyceridemic waist phenotype. 23 After the 12-week weight management program, the intervention group showed significant weight loss, associated with a reduced BMI, whereas the reference group had significantly increased BMI, as a result of body weight gain (time interaction between the 2 groups: P < 0.001).
Along with their abdominal obesity, all study patients depicted, at baseline, a deteriorated metabolic risk profile, which included elevated triglycerides (³1.70 mmol/L), low HDL cholesterol concentrations (<1.0 mmol/L), and an elevated cholesterol-HDL cholesterol ratio (>6.0). 22 Table 1 also shows that the intervention group significantly decreased their cholesterol-HDL cholesterol ratio (P = 0.04) during the 12-week period, mainly owing to an increased HDL cholesterol concentration that did not reach statistical significance (P = 0.07).
The interesting impact on the metabolic profile was obtained with a moderate physical activity level combined with nutritional intervention and behavioural education. Patients trained for 22.8 sessions (mean, SD 5.8), which represent an overall adherence to exercise prescription of 95.1%. This adherence to exercise prescription induced a significant improvement of the aerobic fitness (P = 0.05).
Discussion
Results of the current pilot study are concordant with those previously reviewed regarding the feasibility and beneficial effects of a weight management program to limit or reduce body weight gain among patients treated with SGAs. 24 However, to our knowledge, it is the first time that improvement of metabolic health after a 12 week-intervention program is shown in this population. It is well documented that weight loss has a powerful effect on cardiovascular risk, 25 as well as on plasma lipoprotein-lipid profile. 26 Moreover, a growing consensus is that when changes in body weight and dietary habits are controlled, exercise training alone can be expected to increase HDL cholesterol and to decrease triglyceride levels, with little or no effect on low-density lipoprotein cholesterol. 14 Although the small sample size of this intervention study was not sufficient to detect significant changes among all metabolic markers, results nevertheless showed a significant decrease in the cholesterol-HDL cholesterol ratio among intervention patients, which is a strong predictor of substantial alterations in metabolic indices predictive of ischemic heart disease risk. 27 These improvements in the metabolic risk profile of the intervention group may also be explained by the decreased waist circumference observed at the end of the pilot program.
Indeed, it was demonstrated that an excess accumulation of visceral adipose tissue is associated with a cluster of metabolic complications that substantially increase coronary heart disease risk. 28 It has also been demonstrated that a modest weight loss in abdominally obese patients is associated with preferential mobilization of visceral adipose tissue, leading to improvement of metabolic risk of coronary heart disease. 29 In conclusion, these preliminary results suggest that a modest weight loss following a simple 12-week intervention program improves the metabolic health of SGA-treated patients, when compared with the reference group.
This pilot study has several limitations. The small sample size might have decreased the power to find differences but did not prevent finding very significant differences. The study duration might have been insufficient to detect metabolic changes. Multiple tests might have increased risk of false positive differences, but those that are significant are highly so, and would have remained significant even if a very stringent, such as a Bonferonni, correction had been used. It is now important to elaborate large well-controlled randomized studies, to evaluate the cost-benefit ratio of such interventions among patients under SGAs and to document useful tools to develop and maintain their motivation. Résultats : Après la période de 12 semaines, les patients témoins ont pris du poids significativement (P = 0,001), tandis que les patients d'intervention affichaient une perte de poids significative et un indice de masse corporelle réduit (P = 0,02); l'interaction entre les groupes : P < 0,01. Cette perte de poids s'accompagnait d'une diminution du cholestérol / taux du cholestérol à lipoprotéines de haute densité (P = 0,04). Globalement, les patients d'intervention ont observé les exercices prescrits à 95,1 %, et cette observance à entraîné une amélioration significative de leur capacité aérobique (P = 0,05).
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Conclusion :
Cette étude pilote suggère que les patients traités aux ADG peuvent bénéficier d'un programme de gestion du poids et améliorer leur santé métabolique, ainsi que leur capacité aérobique.
